Data from the first animal study in EKC, demonstrated a rapid clinical response (within 3 days post-treatment with nanoviricides) as indicated by a statistically significant increase in prevention of conjunctival injection (redness, dilation and prominence of conjunctival blood vessels) and blepharitis (crusting, discharge and inflammation of the eyelid margins) when compared with the control group which received an inactive drop preparation  . These results have been confirmed by additional results, indicating that both of the nanoviricide drug candidates evaluated in its pilot study were found to be clinically highly effective against EKC caused by an adenovirus in a rabbit model. Both nanoviricides significantly reduced conjunctival injection (severe redness of the eye) as well as blepharitis (exudate, swelling, matting of fur). The best nanoviricide drug candidates showed excellent long-term results. There were no sub-epithelial infiltrates (SEIs) in animals treated with this nanoviricide (0% incidence). In contrast, 83% incidence of SEIs was seen in vehicle-treated animals, and a 100% incidence of SEIs occurred in untreated infected animals. SEIs are caused by local T cell-mediated immune response to the adenovirus, leading to hazy spots in the cornea. Occurrence of SEIs in the human eye can lead to decreased visual acuity for as long as 2 years  .